Stock analysts at Zacks Research upped their FY2027 earnings per share estimates for GSK in a report issued on Tuesday, March ...

GSK’s Blujepa receives US FDA nod to treat uncomplicated urinary tract infections in female and paediatric patients 12 years of age and older: Philadelphia Friday, March 28, 202 ...

American Depositary Receipts (ADR) are US-listed securities that represent shares in foreign companies, allowing American investors to gain exposure to international equities without dealing with ...

The FDA approved GSK's Blujepa for uncomplicated UTIs in female adults and pediatric patients, with phase 3 trials showing strong efficacy vs. nitrofurantoin.

The US Food and Drug Administration (FDA) has approved GSK’s triazaacenaphthylene antibiotic, Blujepa (gepotidacin), for ...

The FDA has approved GSK’s Blujepa for the treatment of female adults and pediatric patients with uncomplicated urinary tract ...

GSK received approval from the Food and Drug Administration for Blujepa to be used as a treatment for some urinary tract infections. Blujepa, or gepotidacin, was approved to treat uncomplicated ...

The London-based pharmaceuticals company said the US Food and Drug administration has approved Blujepa for the treatment of uncomplicated UTIs in female adults and paediatric patients 12 years of age ...

For much of her early career, Shobie Ramakrishnan called Silicon Valley home. GSK’s chief digital and technology officer ...

Farther Finance Advisors LLC decreased its holdings in shares of GSK plc (NYSE:GSK – Free Report) by 27.4% during the fourth ...

GSK’s chief commercial officer Luke Miels said the company expects its vaccine sales to decrease this year in part due to ...